Often, there is a gulf between scientific research and clinical care. The researchers who study the causes and possible cures for diseases such as cancer are a step removed from the clinicians who provide care and from the patients who suffer the conditions, even though both types of professionals have the same ultimate goal.
Since mankind’s first voyage into space, research and discovery have continued to unlock the mysteries and potential of this vast frontier beyond Earth’s borders. Today, scientific exploration continues to evolve, unveiling new opportunities to enhance and expand the scope of life science through microgravity studies.
Since 1999, MIT has been honoring select scientists, researchers and inventors who change the landscape of their chosen field. This year’s list of “35 Innovators Under 35” showcases the most important emerging technologies of the moment, from reusable rockets to potentially life-saving treatments.
Three researchers who recently the Nobel Prize in Chemistry described the previously indescribable, altering the future of chemistry and science. They provided knowledge about the molecular causes of several diseases, and about mechanisms behind cancer development. Their research also may make you think twice next time you take a deep breath.
Odds are if you’re in a laboratory space, you’re taking precautions against at least one threat category. What about the physical hazards? Are you protected against noise pollution? How big of a problem is it really, and how can lab design and equipment choices affect risk mitigation?
Biologists are adopting a powerful new approach to structural analysis that uses sophisticated computational tools to integrate molecular-scale information from electron microscopy (EM) with atomic-scale results from X-ray crystallography and nuclear magnetic resonance (NMR).
Within every person, somewhere among the approximately 3 billion DNA base pairs, hidden in the alleles and single nucleotide polymorphisms, is the information that defines much of an individual’s physical appearance. This DNA-determined appearance, or phenotype, is what creates family resemblance.
Today, there are a variety of factors impacting supply chain strategy and ultimately labeling processes. Therefore, it’s important to take a close look at what changes are driving today’s trends in labeling, which has become a mission-critical component in the supply chain as businesses continue to expand globally.
If you could see into the future, you would know what tomorrow’s finest products will be and understand the most effective methods to produce them. Many companies are evaluating their work practices and IT infrastructures in an effort to remove the barriers to innovation and improve efficiency in every aspect of their laboratories.
As is often the case in scientific research, sometimes the biggest results can come from the smallest particles. Nanoimaging, or the process of using advanced imaging techniques to view and characterize structures with nanometer resolution, accomplishes just that.
On back-to-back days in late September, a specialty tuberculosis drug saw its price raised 2,600 percent, while a 62-year-old drug that is the standard of care for life-threatening infectious diseases experienced a 5,000 percent overnight increase. The health care industry is currently trapped between serving its patients and enabling pharmaceutical innovation.
Safety is of utmost importance in any laboratory, but recent news that has made it into mainstream media has prompted questions as to exactly how labs keep their personnel—and the general public—safe. Two plans for enhanced lab safety protocols from academia and government have emerged amidst this background of events.
Fifty years of texture research has developed a set of definitions relating the sensory properties of a product to the instrumental properties that can be calculated from the results of a two-cycle texture profile analysis (TPA) test.
Last month, David Sharp and his fellow colleagues at the Albert Einstein College of Medicine, Bronx, N.Y., received a $1.2 million grant from New York State to advance their promising technology for treating paralysis and other effects of spinal cord injuries (SCI).
Here’s an unfortunate riddle: What affects as many as 25,000 Americans, but receives only a small slice of the pharmaceutical funding pie? The answer is an orphan disease. There are more than 6,000 orphan diseases known today ranging from well-known ALS to little-known NGLY1.